Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, NRX Pharmaceuticals Inc maintains a gross margin of 49.17%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1701.65%, while the net margin is -2433.88%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively NRXP converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, NRXP competes directly with industry leaders such as MGX and CLNN. With a market capitalization of $57.53M, it holds a significant position in the sector. When comparing efficiency, NRXP's gross margin of 49.17% stands against MGX's 100.00% and CLNN's 100.00%. Such benchmarking helps identify whether NRX Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
